The market is broadening as PET imaging tracks down applications beyond oncology. PET is progressively used in nervous system science, cardiology, and other clinical strengths for a scope of demonstrative purposes. The growing extent of PET applications widens the market's range and enlivens interest for these devices in different clinical fields.
The segment shift toward a maturing populace adds to the development of the PET devices market. With maturing comes an expanded gamble of persistent illnesses, including cancer development and neurodegenerative circumstances, where PET imaging is instrumental in determination and management. The segment patterns line up with the growing utilization of PET devices in healthcare.
The encounters of worldwide health crises, like the Coronavirus pandemic, highlight the significance of demonstrative imaging in crisis readiness. PET devices, with their capacity to give practical and metabolic data, assume a part in overseeing and grasping illnesses. The awareness acquired during such crises emphatically impacts the reception of PET innovation.
Government drives and subsidizing for healthcare framework impact the reception of PET devices. Monetary assistance, research awards, and great healthcare arrangements add to the availability and reasonableness of PET imaging administrations. Government shifts assumes an essential part in forming the market scene and guaranteeing unlimited accessibility of PET innovation.
The joining of PET devices with artificial intelligence advancements is an arising pattern in the market. Simulated intelligence upgrades picture investigation, understanding, and demonstrative precision, improving the utility of PET imaging. The collaboration between PET devices and artificial intelligence adds to additional proficient and exact clinical results, affecting market predispositions.
Report Attribute/Metric | Details |
---|---|
Growth Rate | Â 6.5% |
The global Positron Emission Tomography Devices Market size is expected to grow at CAGR of 6.5% to reach USD 1.06 Billion during the forecasted 2023-2032.
Contrast media injectors are medical devices utilized to inject CM into the body to enhance the visibility of tissues for different medical imaging procedures. These procedures include computed tomography, magnetic resonance imaging, positron emission tomography, or magnetic resonance. CM injectors find extensive applications in radiology, interventional cardiology, ambulatory surgical centers, and diagnostic imaging centers across the globe. They have evolved from simple, manual injectors to automated injectors that precisely control the amount of the CM agent used, facilitate automated data collection, and warn about potential hazards, such as air embolisms or extravasations.
Some of the factors driving the market growth include the increasing demand for PET analysis in radiopharmaceuticals and the integration of X-ray tomography into PET. According to the World Nuclear Association April 2021, around 10,000 hospitals use radioisotopes in medicine worldwide, and about 90% of the procedures are for diagnosis. As per the same source, in developed countries, the frequency of diagnostic nuclear medicine is 1.9% per year, and the frequency of therapy with radioisotopes is about one-tenth.
June 2024: Siemens Healthineers, a prominent medical equipment company, has obtained permission from the US Food and Drug Administration (FDA) for its Biograph Trinion PET/CT scanner. The PET/CT scanner incorporates a novel air-cooled, digital detector that utilizes lutetium oxyorthosilicate (LSO) crystal components.
The Biograph Trinion is a unified platform that combines PET, CT, and post-processing operations into a single device, with a time of flight (TOF) of 239 picoseconds (ps). Siemens Healthineers has announced that their integrated post-processing imaging applications encompass oncology, theranostics (a fusion of diagnostics and therapies for the identification and treatment of certain types of cancer), cardiovascular imaging, and neurology imaging (including Alzheimer's disease).
The positron emission tomography devices (PET) market is segmented based on product type, applications, end user and region.
The global market for positron emission tomography devices (PET), by product type is segmented into full ring PET scanners and partial ring PET scanners.
The market, by applications, is segmented into cardiology, neurology, oncology, orthopaedics, urology, gastroenterology, and others.
Based on end user, positron emission tomography devices (PET) market is segmented into hospitals, clinics, diagnostic centres, and others. The hospitals segment is anticipated to hold the largest market share owing to the increasing cases of cancer. The diagnostic centres are expected to grow at the highest CAGR owing to the rising demand for early diagnosis.
In the current scope of the study, the above-mentioned segments are covered into the four global regions, namely the Americas, Europe, Asia-Pacific and the Middle East & African region.
The positron emission tomography devices (PET) market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European positron emission tomography devices (PET) market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The positron emission tomography devices (PET) market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The positron emission tomography devices (PET) market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
The Americas dominated the global market for positron emission tomography devices (PET) owing to presence of major market players and increased prevalence of Alzheimer's dementia within the region. As per the data suggested by the Alzheimer's Association, an estimated 5.7 million Americans of all ages are living with Alzheimer's dementia in 2018.
Europe is expected to hold the second largest position in the global positron emission tomography devices (PET) market. The market growth in this region is attributed to the government support and improving healthcare related research & development activities.
Asia Pacific was projected to be the fastest growing region in 2017. Factors such as, growing cases of head and neck cancer, and increasing healthcare expenditure drives the regional markets of the Asia Pacific region. According to the 2018 data suggested by the Australian Institute of Health and Welfare, around 5,091 new cases of head and neck cancer were diagnosed and around 1,034 number of deaths occurred from head and neck cancer in Australia.
On the other hand, the Middle East and Africa held least share in the global positron emission tomography devices (PET) market due to the low per capita income, especially within the African region.
Some of the key players in the global positron emission tomography devices (PET) market are
Research Methodology
Market Research Future research is conducted by industry experts who offer insights into industry structure, market segmentation, assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analysing historical trends and current market positions. Furthermore, the varying trends of segments and categories geographically presented are studied and are estimated based on the primary and secondary research.
Extensive primary research was conducted to gain a deeper insight of the market and the industry performance. In this particular report we have conducted primary surveys (interviews) with key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.
Secondary research was mainly used to collect and identify information useful for extensive, technical, market-oriented, and commercial study of the Positron Emission Tomography Devices (PET). It was also used to obtain key information about major players, market classification, and segmentation according to industry trends, geographical markets, and developments related to the market and perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company web sites, international organization of chemical manufacturers, some paid databases, and many others.
Recent Development
May 2021
In May 2021, GE Healthcare strengthened its PET imaging portfolio with the acquisition of Zionexa, a prominent innovator of in vivo oncology and neurology biomarkers that help enable more personalized healthcare. Thus, the above factors are expected to drive market growth. However, factors such as the shorter half-life of radioisotopes and stringent regulatory guidelines are expected to impede market growth in the near future.
November 2020
According to a research study by Adeline N. Boettcher et al., published in Radiology Imaging Cancer in November 2020, the postponement of routine screening examinations is expected to result in delays in new cancer diagnoses.
Intended Audience
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)